Nektar Therapeutics (NKTR)
NASDAQ: NKTR · IEX Real-Time Price · USD
1.390
+0.040 (2.96%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Nektar Therapeutics Employees
Nektar Therapeutics had 137 employees as of December 31, 2023. The number of employees decreased by 79 or -36.57% compared to the previous year.
Employees
137
Change (1Y)
-79
Growth (1Y)
-36.57%
Revenue / Employee
$658,153
Profits / Employee
-$1,283,504
Market Cap
255.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
MultiPlan | 2,800 |
AirSculpt Technologies | 381 |
Codexis | 174 |
Monte Rosa Therapeutics | 133 |
Zentalis Pharmaceuticals | 124 |
Inovio Pharmaceuticals | 122 |
Sanara MedTech | 108 |
Nanobiotix | 102 |
NKTR News
- 5 weeks ago - Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 - PRNewsWire
- 7 weeks ago - Nektar Management to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Nektar Therapeutics Reports First Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets - PRNewsWire
- 3 months ago - Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases - GlobeNewsWire
- 4 months ago - Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 4 months ago - Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata - PRNewsWire
- 4 months ago - Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results - PRNewsWire